THE TLR AGONIST PROFILIN PROTEIN FROM TOXOPLASMA GONDII GENERATES PROTECTION IN AN EXPERIMENTAL VACCINE

ARCON N; PICCHIO MS; SANCHEZ VR; FENOY IM; MORETTA R; PERRONE SIBILIA MD; SOTO AS; ALDIRICO MA; GOLDMAN A; MARTIN V

CABA

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

Toxoplasmosis is a disease that affects 30% of the world?s population.At present, there are no pharmacological treatments thateliminate the parasite or vaccines that confer protection to the host.In this work, we studied the adjuvant and/or immunogenic value of arecombinant form of T. gondii Profilin protein (rTgPF), a TLR ligand,in a vaccine strategy using a murine model of chronic toxoplasmosis.BALB/c mice were intradermal immunized 3 times with a 2-weekinterval with: rGRA7 (recombinant T. gondii dense granule 7 protein),rTgPF, rGRA7+rTgPF or rGRA7+ACF.The anti-GRA7 humoralresponse showed a Th1 profile when rTgPF was used as adjuvant(IgG1/IgG2a ratio: 0,6±0,5), while rGRA7+ACF showed a mixedprofile (IgG1/IgG2a ratio: 1,3±0,5). Splenocytes from rGRA7+rTgPFand rGRA7+ACF mice stimulated with rGRA7, showed similar levelsof proliferative responses that were significantly higher than the controlgroup (p